<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1306233798
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Amlovan
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amlovan tablets contain two substances called amlodipine and valsartan. Both of these substances help to control high blood pressure.</p><p>&bull; Amlodipine belongs to a group of substances called &ldquo;calcium channel blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel wall which stops the blood vessels from tightening.</p><p>&bull; Valsartan belongs to a group of substances called &ldquo;angiotensin-II receptor antagonists&rdquo;.</p><p>Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II. This means that both of these substances help to stop the blood vessels tightening. As a result, the blood vessels relax and blood pressure is lowered. Amlovan is used to treat high blood pressure in adults whose blood pressure is not controlled enough with either amlodipine or valsartan on its own.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; If you are allergic to amlodipine or to any other calcium channel blockers. This may involve itching, reddening of the skin or difficulty in breathing. &bull; If you are allergic to valsartan or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, talk to your doctor before taking Amlovan.</p><p>&bull; If you have severe liver problems or bile problems such as biliary cirrhosis or cholestasis.</p><p>&bull; If you are more than 3 months pregnant. (It is also better to avoid Amlovan in early pregnancy, see Pregnancy section).</p><p>&bull; If you have severe low blood pressure (hypotension).</p><p>&bull; If you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).</p><p>&bull; If you suffer from heart failure after a heart attack.</p><p>&bull; If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>&nbsp;</p><p><strong>If any of the above applies to you, do not take Amlovan and talk to your doctor. </strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Amlovan:</p><p>&bull; If you have been sick (vomiting or diarrhoea).</p><p>&bull; If you have liver or kidney problems.</p><p>&bull; If you have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.</p><p>&bull; If you have a condition affecting the renal glands called &ldquo;primary hyperaldosteronism&rdquo;.</p><p>&bull; If you have had heart failure or have experienced a heart attack. Follow your doctor&rsquo;s instructions for the starting dose carefully. Your doctor may also check your kidney function.</p><p>&bull; If your doctor has told you that you have a narrowing of the valves in your heart (called &ldquo;aortic or mitral stenosis&rdquo;) or that the thickness of your heart muscle is abnormally increased (called &ldquo;obstructive hypertrophic cardiomyopathy&rdquo;).</p><p>&bull; If you have experienced swelling, particularly of the face and throat, while taking other medicines (including angiotensin converting enzyme inhibitors). If you get these symptoms, stop taking Amlovan and contact your doctor straight away. You should never take Amlovan again.</p><p>&bull; If you are taking any of the following medicines used to treat high blood pressure:</p><p>o An ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>o Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading &ldquo;Do not take Amlovan&rdquo;.</p><p>&nbsp;</p><p><strong>If any of these apply to you, tell your doctor before taking Amlovan.</strong></p><p><strong>Children and adolescents</strong></p><p>The use of Amlovan in children and adolescents is not recommended (aged below 18 years old).</p><p><strong>Other medicines and Amlovan </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change your dose and/or to take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below:</p><p>&bull; ACE inhibitors or aliskiren (see also information under the headings &ldquo;Do not take Amlovan&rdquo; and &ldquo;Warnings and precautions&rdquo;) .</p><p>&bull; Diuretics (a type of medicine also called &ldquo;water tablets&rdquo; which increases the amount of urine you produce).</p><p>&bull; Lithium (a medicine used to treat some types of depression) .</p><p>&bull; Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels.</p><p>&bull; Certain types of painkillers called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 inhibitors (COX-2 inhibitors). Your doctor may also check your kidney function.</p><p>&bull; Anticonvulsant agents (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone).</p><p>&bull; St. John&rsquo;s wort.</p><p>&bull; Nitroglycerin and other nitrates, or other substances called &ldquo;vasodilators&rdquo;.</p><p>&bull; Medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir).</p><p>&bull; Medicines used to treat fungal infections (e.g. ketoconazole, itraconazole).</p><p>&bull; Medicines used to treat bacterial infections (such as rifampicin, erythromycin, clarithromycin, talithromycin).</p><p>&bull; Verapamil, diltiazem (heart medicines).</p><p>&bull; Simvastatin (a medicine used to control high cholesterol levels).</p><p>&bull; Dantrolene (infusion for severe body temperature abnormalities).</p><p>&bull; Medicines used to protect against transplant rejection (ciclosporin).</p><p><strong>Amlovan with food and drink</strong></p><p>Grapefruit and grapefruit juice should not be consumed by people who are taking Amlovan. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Amlovan.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Pregnancy You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Amlovan before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Amlovan. Amlovan is not recommended in early pregnancy (first 3 months), and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. Amlodipine has been shown to pass into breast milk in small amounts. Amlovan is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breastfeed, especially if your baby is newborn, or was born prematurely. Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>This medicine may make you feel dizzy. This can affect how well you can concentrate. So, if you are not sure how this medicine will affect you, do not drive, use machinery, or do other activities that you need to concentrate on.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects. The usual dose of Amlovan is one tablet per day.</p><p>&bull; It is preferable to take your medicine at the same time each day.</p><p>&bull; Swallow the tablets with a glass of water.</p><p>&bull; You can take Amlovan with or without food. Do not take Amlovan with grapefruit or grapefruit juice.</p><p>Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>Do not exceed the prescribed dose.</p><p>&nbsp;</p><p><strong>Amlovan and older people (age 65 years or over) </strong></p><p>Your doctor should exercise caution when increasing your dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p><strong>If you take more Amlovan than you should</strong></p><p>If you have taken too many tablets of Amlovan, or if someone else has taken your tablets, consult a doctor immediately.</p><p><strong>If you forget to take Amlovan </strong></p><p>If you forget to take this medicine, take it as soon as you remember. Then take your next dose at its usual time. However, if it is almost time for your next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Amlovan </strong></p><p>Stopping your treatment with Amlovan may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects can be serious and need immediate medical attention: </strong></p><p>A few patients have experienced these serious side effects (may affect up to 1 in 1,000 people).</p><p><strong>If any of the following happen, tell your doctor straight away:</strong></p><p>Allergic reaction with symptoms such as rash, itching, swelling of face or lips or tongue, difficulty breathing, low blood pressure (feeling of faintness, light-headedness).</p><p><strong>Other possible side effects of Amlovan:</strong></p><p><em>Common (may affect up to 1 in 10 people)</em>: Influenza (flu); blocked nose, sore throat and discomfort when swallowing; headache; swelling of arms, hands, legs, ankles or feet; tiredness; asthenia (weakness); redness and warm feeling of the face and/or neck.</p><p><em>Uncommon (may affect up to 1 in 100 people):</em> Dizziness; nausea and abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands or feet; vertigo; fast heart beat including palpitations; dizziness on standing up; cough; diarrhoea; constipation; skin rash, redness of the skin; joint swelling, back pain; pain in joints.</p><p><em>Rare (may affect up to 1 in 1,000 people):</em> Feeling anxious; ringing in the ears (tinnitus); fainting; passing more urine than normal or feeling more of an urge to pass urine; inability to get or maintain an erection; sensation of heaviness; low blood pressure with symptoms such as dizziness, lightheadedness; excessive sweating; skin rash all over your body; itching; muscle spasm.</p><p><strong>If any of these affect you severely, tell your doctor. </strong></p><p><strong>Side effects reported with amlodipine or valsartan alone and either not observed with Amlovan or observed with a higher frequency than with Amlovan:</strong></p><p>Amlodipine</p><p>Consult a doctor immediately if you experience any of the following very rare, severe side effects after taking this medicine:</p><p>- Sudden wheeziness, chest pain, shortness of breath or difficulty in breathing.</p><p>- Swelling of eyelids, face or lips.</p><p>- Swelling of the tongue and throat which causes great difficulty breathing.</p><p>- Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson Syndrome - toxic epidermal necrolysis) or other allergic reactions.</p><p>- Heart attack, abnormal heart beat.</p><p>- Inflamed pancreas, which may cause severe abdominal and back pain accompanied with feeling of being very unwell.</p><p>The following side effects have been reported. If any of these cause you problems or if they last for more than one week, you should contact your doctor.</p><p><em>Common (may affect up to 1 in 10 people):</em> Dizziness, sleepiness; palpitations (awareness of your heart beat); flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea).</p><p><em>Uncommon (may affect up to 1 in 100 people)</em>: Mood changes, anxiety, depression, sleeplessness, trembling, taste abnormalities, fainting, loss of pain sensation; visual disturbances, visual impairment, ringing in the ears; low blood pressure; sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis); indigestion, vomiting (being sick); hair loss, increased sweating, itchy skin, skin discolouration; disorder in passing urine, increased need to urinate at night, increased number of times of passing urine; inability to obtain an erection, discomfort or enlargement of the breasts in men, pain, feeling unwell, muscle pain, muscle cramps; weight increase or decrease.</p><p><em>Rare (may affect up to 1 in 1,000 people): </em>Confusion.</p><p>Very rare (may affect up to 1 in 10,000 people): Decreased number of white blood cells, decrease in blood platelets which may result in unusual brusing or easy bleeding (red blood cell damage); excess sugar in blood (hyperglycaemia); swelling of the gums, abdominal bloating (gastritis); abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests; increased muscle tension; inflammation of blood vessels often with skin rash, sensitivity to light; disorders combining rigidity, tremor and/or movement disorders.</p><p>Valsartan</p><p><em>Not known (frequency cannot be estimated from the available data): </em>Decrease in red blood cells, fever, sore throat or mouth sores due to infections; spontaneous bleeding or bruising; high level of potassium in the blood; abnormal liver test results; decreased renal functions and severely decreased renal functions; swelling mainly of the face and the throat; muscle pain; rash, purplishred spots; fever; itching; allergic reaction; blistering skin (sign of a condition called dermatitis bullous).</p><p>If you experience any of these, tell your doctor straight away.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use any Amlovan pack that is damaged or shows signs of tampering.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substances of Amlovan are amlodipine (as amlodipine besylate) and valsartan. Each film-coated tablet of Amlovan 5 mg/160 mg contains 5 mg amlodipine and 160 mg valsartan. Each film-coated tablet of Amlovan 10 mg/160 mg contains 10 mg amlodipine and 160 mg valsartan.</p><p>&bull; The other ingredients are:</p><p>Amlovan film-coated tablets contain:</p><p>Tablet Core: Avicel PH 102, Crospovidone NF, Colloidal Silicon Dioxide, and Magnesium Stearate.</p><p>Tablet coating: Instacoat Universal A05G11327 Yellow, Instacoat Universal A05G11323 Yellow, and Purified Water BP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Amlovan 5 mg/160 mg film-coated tablet is a dark yellow colored, oval shaped biconvex, 
Film- coated tablet, engraved with "252" on one side and plain on the other side. 

Amlovan 10 mg/160 mg film-coated tablet is a light yellow colored, oval shaped biconvex, 
film- coated tablet, engraved with "253" on one side and plain on the other side. 

Each pack of Amlovan contains 28 film-coated tablets (7 tablets/ blister). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 March 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ﺗﺤﺘﻮي أﻗﺮاص أﻣﻠﻮﭬﺎن ﻋﻠﻰ ﻣﺎدﺗين&nbsp;هما&nbsp; أملوديبين&nbsp;و ﭬﺎﻟﺴﺎرﺗﺎن. ﺗﺴﺎﻋﺪ ﻛﻼ المادتين&nbsp;ﻓﻲ السيطرة&nbsp;ﻋﻠﻰ ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم.</p><p dir="RTL">&middot; &nbsp;ينتمي أملوديبين إﻟﻰ ﻣﺠﻤﻮﻋﺔ ﻣﻦ ﻣﻮاد ﺗﺴﻤﻰ &quot;ﺣﺎﺻﺮات ﻗﻨﺎة الكالسيوم .&quot; يوقف&nbsp; أملوديبين الكالسيوم ﻣﻦ اﻟﺘﺤﺮك ﻓﻲ</p><p dir="RTL">ﺟﺪار اﻟﻮﻋﺎء اﻟﺪﻣﻮي و ﺑﺬﻟﻚ يمنع الاوعيه الدموية من التضييق .</p><p dir="RTL">&middot;&nbsp; &nbsp; ينتمي &nbsp;ﭬﺎﻟﺴﺎرﺗﺎن إﻟﻰ ﻣﺠﻤﻮﻋﺔ ﻣﻦ ﻣﻮاد ﺗﺴﻤﻰ &quot;ﻣﻀﺎدات ﻣﺴﺘﻘﺒﻼت انجيوتنسين-&nbsp;<strong>II&nbsp;</strong> يتم إﻧﺘﺎج انجيوتنسين-&nbsp;<strong>II&nbsp;</strong>ﻓﻲ</p><p dir="RTL">اﻟﺠﺴﻢ، ويجعل الاوعية الدموية اكثرا ضيقا&nbsp; وﺑﺎﻟﺘﺎﻟﻲ زيادة ﺿﻐﻂ اﻟﺪم. يعمل ﭬﺎﻟﺴﺎرﺗﺎن ﻋﻦطريق منع تأثير&nbsp;انجيوتنسين-&nbsp;<strong>II</strong></p><p dir="RTL">وهذا يعني&nbsp;أن ﻛﻼ ﻣﻦ هذه اﻟﻤﻮاد ﺗﺴﺎﻋﺪ ﻋﻠﻰ ﻣﻨﻊ الاوعية الدموية ﻣﻦ التضييق . ونتيجة لذلك يحدث استرخاء في الاوعية الدموية وينخفض ضغط الدم&nbsp;&nbsp;.</p><p dir="RTL">يستخدم أﻣﻠﻮﭬﺎن ﻟﻌﻼج ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم ﻟﺪى البالغين الذين لم يتم التحكم في ضغط الدم بما فيه الكفاية ﻣﻊ أي أملوديبين&nbsp;أو ﭬﺎﻟﺴﺎرﺗﺎن بمفردهم .&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول أملوڤان </strong></p><p>&bull; إذا كان لديك حساسية من أملوديبين أو أي حاصرات قناة الكالسيوم الأخرى. وقد ينطوي هذا على حكة، احمرار الجلد أو صعوبة في التنفس.</p><p>&bull; إذا كان لديك حساسية من ڤالسارتان أو أي من المكونات الأخرى من هذا الدواء (المدرجة في القسم 6).</p><p>إذا كنت تعتقد&nbsp;أنك قد تكون لديك حساسية، تحدث مع طبيبك قبل تناول أملوڤان.</p><p>&bull; إذا كان لديك مشاكل شديدة في الكبد أو مشاكل الصفراء مثل تليف الكبد الصفراوي أو ركود صفراوي.</p><p>&bull; إذا كنت أكثر من 3 أشهر من الحمل. (بل يفضل تجنب أملوڤان في مرحلة مبكرة من الحمل، انظر قسم الحمل).</p><p>&bull; إذا كان لديك انخفاض شديد في ضغط الدم (انخفاض ضغط الدم).</p><p>&bull; إذا كان لديك ضيق في الصمام الأورطى (تضيق الأورطي) أو صدمة قلبية (حالة تحدث حين يكون القلب غير قادر على توفير ما يكفي من الدم إلى الجسم).</p><p>&bull; إذا كنت تعاني من فشل في القلب بعد الإصابة بأزمة قلبية.</p><p>&bull; إذا كان لديك مرض السكري أو اختلال في وظائف الكلى ويتم علاجك باستخدام دواء لخفض ضغط الدم يحتوي على أليسكيرين.</p><p><strong>إذا كان أي من ما سبق ينطبق عليك، لا تتناول أملوڤان وتحدث مع طبيبك. </strong></p><p><strong>التحذيرات والاحتياطات&nbsp;</strong></p><p>تحدث مع طبيبك قبل تناول أملوڤان:</p><p>&bull; إذا كنت تشعر بالمرض (القيء أو الإسهال).</p><p>&bull; إذا كان لديك مشاكل في الكبد أو الكلى.</p><p>&bull; إذا خضعت لعملية زرع الكلى أو إذا كنت قد قيل لك أن لديك ضيق في شرايين الكلى الخاصة بك.</p><p>&bull; إذا كان لديك حالة تصيب الغدد الكلوية تسمى &quot;فرط الألدوستيرونيزم&nbsp; الأساسي&quot;.</p><p>&bull; إذا كان لديك فشل القلب أو تعرضت لأزمة قلبية. اتبع تعليمات الطبيب للجرعة المبدئية بعناية. قد يتحقق طبيبك أيضا من وظيفة الكلى الخاصة بك.</p><p>&bull; إذا قال لك طبيبك أن لديك ضيق في صمامات قلبك (ويسمى &quot;تضيق الصمام الأورطي أو المترالي&quot;) أو أن سمك عضلة القلب يزداد بشكل غير طبيعي (و يسمى &quot;اعتلال عضلة القلب التضخمي الانسدادي&quot;).</p><p>&bull; إذا واجهت تورم، وخاصة في الوجه والحلق، أثناء تناول أدوية أخرى (بما في ذلك مثبطات انزيم تحول أنجيوتنسين). اذا كان لديك هذه الأعراض توقف عن تناول أملوڤان واتصل بطبيبك على الفور. يجب أن لا تتناول أملوڤان مرة أخرى.</p><p>&bull; إذا كنت تتناول أي من الأدوية التالية التي تستخدم لعلاج ارتفاع ضغط الدم:</p><p>o مثبط انزيم تحول أنجيوتنسين (على سبيل المثال إنالابريل، ليزينوبريل، راميبريل)، ولا سيما إذا كان لديك مشاكل في الكلى المتعلقة بالسكري.</p><p>o أليسكيرين.</p><p>قد يتحقق طبيبك من وظيفة الكلى وضغط الدم الخاص بك ، وكمية الشوارد (مثل البوتاسيوم) في الدم على فترات منتظمة. انظر أيضا المعلومات تحت عنوان &quot;لا تتناول أملوڤان&quot;</p><p>إذا كان أي من هذه الحالات تنطبق عليك، أخبر طبيبك قبل تناول أملوڤان.</p><p><strong>الأطفال والمراهقين </strong></p><p>لا ينصح استخدام أملوڤان في الأطفال والمراهقين (أعمارھم أقل من 18 سنة).</p><p>الأدوية أخرى و أملوڤان أخبر طبيبك أو الصيدلي إذا كنت تتناول ، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى. قد يحتاج طبيبك إلى تغيير الجرعة و / أو اتخاذ الاحتياطات الأخرى. في بعض الحالات قد تضطر إلى التوقف عن تناول أحد هذه الأدوية. هذاينطبق بشكل خاص على الأدوية المذكورة أدناه:</p><p>&bull; مثبطات انزيم تحول أنجيوتنسين أو أليسكيرين (انظر أيضا المعلومات تحت عناوين &quot;لا تتناول أملوڤان&quot; و &quot;التحذيرات والاحتياطات&quot;).</p><p>&bull; مدرات البول (نوع من الأدوية تسمى أيضا &quot;أقراص المياه&quot; مما يزيد من كمية البول التي تنتج).</p><p>&bull; الليثيوم (دواء يستخدم لعلاج بعض أنواع الاكتئاب).</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻣﺪرات اﻟﺒﻮل اﻟﺘﻲ ﺗﻘﺘﺼﺪ ﻓﻲ اﻟﺒﻮﺗﺎسيوم، و ﻣﻜﻤﻼت اﻟﺒﻮﺗﺎسيوم، وﺑﺪاﺋﻞ اﻟﻤﻠﺢ اﻟﺘﻲ ﺗﺤﺘﻮي ﻋﻠﻰ اﻟﺒﻮﺗﺎسيوم</p><p dir="RTL">وﻏيرها ﻣﻦ اﻟﻤﻮاد اﻟﺘﻲ ﻗﺪ ﺗزيد ﻣﻦ ﻣﺴﺘويات&nbsp;اﻟﺒﻮﺗﺎسيوم</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;أﻧﻮاع معينةﻣﻦ اﻟﻤﺴﻜﻨﺎت ﺗﺴﻤﻰ اﻷدوية اﻟﻤﻀﺎدة ﻟﻼلتهابات غير الستيرودية ( اﻟﻤﺴﻜﻨﺎت ) أو ﻣﺜﺒﻄﺎت اﻷﻛﺴﺪة</p><p dir="RTL">اﻟﺤلقية 2 اﻻﻧﺘﻘﺎﺋية( ﻣﺜﺒﻄﺎت&nbsp;<strong>COX-2</strong>&nbsp;) ﻗﺪ يتحقق&nbsp;طبيبك&nbsp;&nbsp;ايضا من وظيفة الخاصة بك&nbsp;</p><p dir="RTL">&middot; &nbsp;&nbsp;الادوية&nbsp; اﻟﻤﻀﺎدة ﻟﻠﺘﺸﻨﺠﺎت ( مثل كاربامازيبين , فينوباربيتال , فينيتوين , فوسفينيتوين , بريميدون )&nbsp;</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻋﺸﺒﺔ ﺳﺎﻧﺖ ﺟﻮن.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻧﺘﺮوجليسرين&nbsp;&nbsp;واﻟﻨﺘﺮات أﺧﺮى، أو ﻣﻮاد أﺧﺮى ﺗﺴﻤﻰ &quot;اﻟﻤﻮﺳﻌﺎت اﻟﻮﻋﺎﺋية .&quot;</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻷدوية &nbsp;اﻟﻤﺴﺘﺨﺪﻣﺔ لفيروس ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ البشرية&nbsp; / الايدز&nbsp;&nbsp;( ﻋﻠﻰ سبيل&nbsp; اﻟﻤﺜﺎل ريتونافير ،امبيرانيفير ، نلفينافير )&nbsp;</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;الادوية&nbsp; اﻟﻤﺴﺘﺨﺪﻣﺔ ﻟﻌﻼج الالتهابات الفطرية ( ﻣﺜﻞ كيتوﻛﻮﻧﺎزول،ايتراﻛﻮﻧﺎزول)</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;االادوية&nbsp; اﻟﻤﺴﺘﺨﺪﻣﺔ ﻟﻌﻼج الالتهابات البكتيرية ( مثل ريفامبيسين , اريثروميسين , كلاريثروميسين , تاليريثرومايسين</p><p dir="RTL">&middot; &nbsp;فيراباميل , ديلتيازيم ( ادوية&nbsp;اﻟﻘﻠﺐ)</p><p dir="RTL">&middot; &nbsp;&nbsp;سيمفاستاتين ( دواء يستخدم للسيطرة على مستويات الكولسترول العالية )&nbsp;</p><p dir="RTL">&middot; &nbsp;دانترولين ( تسريب للتغيرات الشديدة في درجة حرارة الجسم )&nbsp;</p><p dir="RTL">&middot; الادوية المستخدمة للحماية من رفض زراعة الاعضاء ( سيكلوسبورين )&nbsp;</p><p dir="RTL"><strong>تناول املوفان مع الطعام والشراب&nbsp;</strong></p><p dir="RTL">يجب عدم تناول جريب فروت او عصير جريب فروت من قبل الناس الذين يتناولون املوڤان , وذلك لان جريب فروت وعصير جريب فروت يمكن ان يؤدي الى زيادة مستويات المادة الفعالة املوديبين في الدم , والتي يمكن ان تسبب زيادة غير متوقعة في تأثير املوڤان في خفض ضغط الدم<strong>&nbsp;.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ا<strong>لحمل والرضاعة الطبيعية</strong></p><p dir="RTL">الحمل</p><p dir="RTL">يجب إخبار الطبيب إذا كنتي تعتقدين أنك (أو قد تصبح) حاملا. سوف ينصحك طبيبك عادة التوقف عن تناول أملوڤان قبل أن تصبحي حاملا أو في أقرب وقت تصبحين فيه حاملا وسوف ينصحك أن تتناولي دواء آخر بدلا من أملوڤان ,&nbsp;لاينصح تناول أملوڤان في مرحلة مبكرة من الحمل (الـ 3 أشهر الأولى)، ويجب ألا يتم تناوله عند أكثر من 3 أشهر من الحمل، لأنه قد يسبب ضررا بالغا لطفلك إذا ما تم تناوله بعد الشهر الثالث من الحمل.</p><p dir="RTL">الرضاعة الطبيعية</p><p dir="RTL">أخبري طبيبك إذا كنتي ترضعين طفلك رضاعة طبيعية أو على وشك أن تبدأي الرضاعة الطبيعية. ثبت أن أملوديبين ينتقل إلى حليب الثدي بكميات صغيرة. لا ينصح تناول أملوڤان للأمهات الذين يرضعن أطفالهن رضاعة طبيعية ، و قد يختار الطبيب علاج آخر لكي إذا كنتي ترغبين في إرضاع طفلك رضاعة طبيعية، وخاصة إذا كان طفلك حديث الولادة، أو ولد قبل الأوان. إسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يجعلك هذا الدواء تشعر بالدوار. و يمكن أن يؤثر هذا&nbsp; الدواء على قدرتك على التركيز جيدا. لذا، إذا كنت غير متأكد من كيفية تأثير هذا الدواء عليك، لا تقود، وتستخدم الآلات، أو تقوم بأنشطة أخرى التي تحتاج إلى التركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تأخذ هذا الدواء دائما كما أخبرك طبيبك. استشر طبيبك إذا لم تكن متأكدا. هذا سوف يساعدك في الحصول على أفضل النتائج وتقليل خطر الأعراض الجانبية.</p><p>الجرعة المعتادة من أملوڤان هي قرص واحد يوميا.</p><p>&bull; من الأفضل تناول الدواء في نفس الوقت كل يوم</p><p>&bull; ابتلع الأقراص مع كوب من الماء.</p><p>&bull; يمكنك أن تتناول أملوڤان مع أو بدون الطعام. لا تتناول أملوڤان مع جريب فروت أو عصير جريب فروت.</p><p>اعتمادا على كيفية الاستجابة للعلاج، قد يقترح طبيبك جرعة أعلى أو أدنى. لا تتجاوز الجرعة الموصوفة.</p><p><strong>أملوڤان وكبار السن (العمر 65 سنة فما فوق)</strong></p><p>يجب على الطبيب &nbsp;توخي الحذر عند زيادة الجرعة. إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.</p><p><strong>إذا كنت تتناول أملوڤان أكثر مما يجب</strong></p><p>إذا كنت قد تناولت الكثير من أقراص أملوڤان، أو إذا تناول شخص آخر أقراصك، يجب استشارة الطبيب فورا.</p><p><strong>إذا كنت قد نسيت أن تتناول أملوڤان</strong></p><p>إذا كنت قد نسيت أن تتناول هذا الدواء، تناوله حالما تتذكر. ثم تناول الجرعة التالية في وقتها المعتاد. ومع ذلك، إذا كان الوقت تقريبا لتناول الجرعة التالية فتجاوز الجرعة المنسية. لا تتناول جرعة مضاعفة لتعويض القرص المنسي.</p><p><strong>إذا توقفت عن تناول أملوڤان</strong></p><p>وقف العلاج بـ أملوڤان قد يزيد المرض سوءا. لا تتوقف عن تناول الدواء ما لم يخبرك طبيبك ذلك .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراض جانبية، على الرغم من أنها لا تحدث للجميع.</p><p><strong>يمكن أن تكون بعض الأعراض الجانبية خطيرة وتحتاج إلى عناية طبية فورية: </strong></p><p>تعرض عدد قليل من المرضى لهذه الأعراض الجانبية الخطيرة (قديؤثر على ما يصل إلى 1 في 1000 شخص).</p><p><strong>إذا كان أي مما يلي يحدث، أخبر طبيبك فورا: </strong></p><p>رد الفعل التحسسي مع أعراض مثل طفح جلدي، حكة، تورم الوجه أو الشفتين أو اللسان، صعوبة في التنفس، وانخفاض ضغط الدم (شعور بالإغماء و الدوار الخفيف).</p><p><strong>الأعراض الجانبية المحتملة الأخرى من أملوڤان: </strong></p><p><strong><em>شائعة (قد تؤثر على ما یصل إلى 1 في 10 أشخاص): </em></strong></p><p>(أنفلونزا)؛ انسداد الأنف، التهاب الحلق وعدم الراحة عند البلع. صداع؛ تورم الذراعين واليدين و الساقين والكاحلين أو القدمين. تعب. وهن (الضعف)؛ احمرار وشعور دافئ للوجه و / أو الرقبة.</p><p><strong><em>غیر شائعة (قد تؤثر على ما یصل إلى 1 في 100 شخص):</em></strong></p><p>دوخة، غثيان وآلام في البطن. جفاف الفم. نعاس، وخز أو خدر في اليدين أو القدمين. دوار؛ ضربات القلب السريعة بما في ذلك الخفقان. دوخة عند الوقوف. سعال؛ إسهال؛ إمساك، طفح جلدي واحمرار الجلد. تورم المفاصل، آلام الظهر. ألم في المفاصل.</p><p><strong><em>نادرة (قد تؤثر على ما یصل إلى 1 في 1000 شخص): </em></strong></p><p>شعور بالقلق. طنين في الأذنين (الطنين)؛ إغماء؛ زيادة التبول أو زيادة الشعور بالرغبة في التبول. عدم القدرة على الحصول أو الحفاظ على الانتصاب. إحساس بالثقل. انخفاض ضغط الدم مع أعراض مثل الدوخة، والدوار. التعرق المفرط. الطفح الجلدي في جميع أنحاء الجسم. الحكة. تشنج العضلات.</p><p><strong>إذا كان أي من هذه تؤثر عليك بشدة، أخبر طبيبك. </strong></p><p><strong>أعراض جانبية تم تقريرها مع أملوديبين أو ڤالسارتان وحده، أو لم يتم ملاحظتها مع أملوڤان أو لوحظت ب تردد أعلى مع أملوڤان: </strong></p><p><u>أملوديبين</u></p><p><strong>استشر الطبيب فورا إذا كنت تواجه أي من الأعراض الجانبية النادرة جدا، الشديدة التالية بعد تناول هذا الدواء:</strong></p><p>- الأزيز المفاجئ، ألم في الصدر، ضيق في التنفس أو صعوبة في التنفس.</p><p>- تورم الجفون والوجه أو الشفتين.</p><p>- تورم اللسان والحلق والذي يسبب صعوبة كبيرة في التنفس.&nbsp;</p><p>- ردود فعل الجلد الشديدة بما في ذلك الطفح الجلدي الكثيف، و الشري احمرار الجلد على الجسم كله ,&nbsp;&nbsp;وحكة شديدة، بثور و تقشير وتورم في الجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون - انحلال البشرة السمي) أو ردود الفعل التحسسية الأخرى.</p><p>- نوبة قلبية، ضربات القلب غير طبيعية.</p><p>- التهاب البنكرياس، مما قديتسبب في آلام بالبطن وآلام الظهر يرافقه الشعور بالإعياء الشديد .</p><p>تم الإبلاغ عن الأعراض الجانبية التالية. إذا كان أي من هذه الحالات تسبب لك مشاكل أو إذا كانت تستمر لأكثر من أسبوع واحد، يجب عليك الاتصال بطبيبك.</p><p><strong>شائعة (قد تؤثر على ما يصل إلى 1 في 10 أشخاص):&nbsp;</strong></p><p>دوخة، نعاس، و خفقان (الوعي بضربات القلب الخاص بك). احمرار، تورم الكاحل (وذمة)؛ آلام في البطن، و شعور بالمرض (غثيان).</p><p><strong>غير شائعة (قد تؤثر على ما يصل إلى 1 في 100 شخص):</strong></p><p>تقلبات في المزاج، والقلق، والاكتئاب، والأرق،والارتجاف ،&nbsp; شذوذ التذوق، الإغماء، فقدان الإحساس بالألم. الاضطرابات البصرية، الإعاقة البصرية، طنين في الأذنين. ضغط دم منخفض؛ العطس / سيلان الأنف الناجم عن التهاب الغشاء المبطن للأنف (التهاب الأنف)؛ عسر الهضم والقيء (الإحساس بالعلة)؛ فقدان الشعر، وزيادة التعرق، وحكة في الجلد، تغير لون الجلد. اضطراب في التبول، وزيادة الحاجة للتبول ليلا، وزيادة عدد مرات التبول. عدم القدرة على الحصول على الانتصاب، وعدم الراحة أو تضخم الثدي في الرجال، والألم، والشعور بالإعياء وآلام في العضلات، وتشنجات العضلات. زيادة أو نقص الوزن.</p><p><strong>نادرة(قد تؤثر على ما يصل إلى 1 في 1000 شخص): </strong></p><p>ارتباك.</p><p><strong>نادرة جدا (قد تؤثر على ما يصل إلى 1 في 10000 شخص):</strong></p><p>انخفاض عدد خلايا الدم البيضاء، وانخفاض في الصفائح الدموية التي قد تؤدي إلى كدمات غير عادية أو سهولة النزيف (تلف خلايا الدم الحمراء)؛ زيادة السكر في الدم (ارتفاع سكر الدم)؛ تورم اللثة والانتفاخ في البطن (التهاب المعدة)؛ نتائج غير طبيعية وظائف الكبد ، والتهاب الكبد (التھاب الكبد)، اصفرار الجلد (الیرقان) زیادة انزیم الكبد التي قديكون لها تأثير على بعض الفحوصات الطبية. زيادة توتر العضلات. التهاب الأوعية الدموية في كثير من الأحيان مع الطفح الجلدي، والحساسية للضوء. اضطرابات تجمع بين صلابة، ورعاش و / أو اضطرابات حركة.</p><p><u>ڤالسارتان</u></p><p>غير معروفة (لا يمكن تقدير تردد من البيانات المتاحة): انخفاض في كريات الدم الحمراء، حمى، التهاب الحلق أو الفم القروح الناجمة عن الالتهابات. نزيف عفوي أو كدمات. مستوى عال من البوتاسيوم في الدم. نتائج غير طبيعية في نتائج وظائف الكبد. انخفاض في وظائف الكلى و انخفاض شديد في وظائف الكلى. تورم أساسا في الوجه والحلق. ألم عضلي؛ طفح جلدي والبقع الأرجواني الأحمر. حمى؛ حكة. رد فعل تحسسي؛ ظهور تقرحات في الجلد (علامة على وجود حالة تسمى التهاب الجلد فقاعية )&nbsp;</p><p>إذا كنت تواجه&nbsp;أي من هذه، أخبر طبيبك فورا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ الدواء بعيدا عن متناول ونظر الأطفال.</p><p>لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة و الشريط.</p><p>لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p>احفظ الدواء في العبوة الأصلية من أجل الحماية من الرطوبة.</p><p>لا تستخدم أي عبوة أملوڤان التي تعرضت للتلف أو علامات العبث.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المواد الفعالة في أملوڤان هي أملوديبين (على هيئة&nbsp;أملوديبين بيسايلات) و ڤالسارتان.&nbsp;</p><p>يحتوي كل قرص مغلف بطبقة رقيقة من أملوڤان 5 ملجم/ 160 ملجم على 5 أملجم ملوديبين و 160&nbsp;ملجم ڤالسارتان.</p><p>يحتوي كل قرص مغلف بطبقة رقيقة من أملوڤان 10 ملجم/ 160 ملجم على 10 ملجم أملوديبين و 160 ملجم ڤالسارتان.</p><p>&bull; المكونات الأخرى هى:</p><p>تحتوي أقراص أملوڤان المغلفة بطبقة رقيقة على:</p><p>لب القرص: أفيسيل بى إتش 102 و كروسبوفيدون إن إف و سيليكون ثنائي التأكسد غروي و ستياريت الماغنسيوم.</p><p>غلاف القرص: إنستاكوت عالمي A05G11327&nbsp;و&nbsp; A05G11323 أصفر و ماء منقى بي بي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص أملوڤان 5 ملجم/&nbsp;160 ملجم المغلف بطبقة رقيقة هو قرص أصفر اللون , بيضوي&nbsp;الشكل ، محدب الوجهين، مغلف بطبقة رقيقة محفور &quot; 252&quot; على أحد السطحين و عادي على السطح الآخر .</p><p>قرص أملوڤان 10 ملجم/ 160 ملجم المغلف بطبقة رقيقة هو قرص أصفر اللون , بيضوي&nbsp;الشكل ، محدب الوجهين، مغلف بطبقة رقيقة محفور &quot;253&quot; على أحد السطحين و عادي على السطح الآخر .</p><p>تحتوي كل عبوة من أملوڤان على 28 قرص مغلف بطبقة رقيقة ( 7 اقراص لكل شريط).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">ﺻﻨﻊ ﺑﻮاﺳﻄﺔ:</p><p dir="RTL"><strong>الدوائية&nbsp;</strong></p><p dir="RTL">مصنع الادوية بالقصيم&nbsp;</p><p dir="RTL">المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AMLOVAN® 5 mg/160 mg film-coated tablets
AMLOVAN® 10 mg/160 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlovan 5 mg/160 mg film-coated tablets: Each film-coated tablet contains 5 mg of amlodipine 
(as amlodipine besylate) and 160 mg of valsartan. 
Amlovan 10 mg/160 mg film-coated tablets: Each film-coated tablet contains 10 mg of 
amlodipine (as amlodipine besylate) and 160 mg of valsartan. 

For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets 

Amlovan 5 mg/160 mg film-coated tablet is a dark yellow colored, oval shaped biconvex, Filmcoated tablet, engraved with "252" on one side and plain on the other side. 

Amlovan 10 mg/160 mg film-coated tablet is a light yellow colored, oval shaped biconvex, 
film- coated tablet, engraved with "253" on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.</p><p>Amlovan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose of Amlovan is one tablet per day.</p><p>Amlovan 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.</p><p>Amlovan 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Amlovan 5 mg/160 mg.</p><p>Amlovan can be used with or without food.</p><p>Individual dose titration with the components (i.e. amlodipine and valsartan) is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered.</p><p>For convenience, patients receiving valsartan and amlodipine from separate tablets/capsules may be switched to Amlovan containing the same component doses.</p><p>&nbsp;</p><p><em>Renal impairment </em></p><p>There are no available clinical data in severely renally impaired patients. No dosage adjustment is required for patients with mild to moderate renal impairment. Monitoring of potassium levels and creatinine is advised in moderate renal impairment.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Amlovan is contraindicated in patients with severe hepatic impairment (see section 4.3). Caution should be exercised when administering Amlovan to patients with hepatic impairment or biliary obstructive disorders (see section 4.4). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan. Amlodipine dosage recommendations have not been established in patients with mild to moderate hepatic impairment. When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Amlovan, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.</p><p>&nbsp;</p><p><em>Elderly (age 65 years or over)</em></p><p>In elderly patients, caution is required when increasing the dosage. When switching eligible elderly hypertensive patients (see section 4.1) to amlodipine or Amlovan, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>The safety and efficacy of Amlovan in children aged below 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Oral use.</p><p>It is recommended to take Amlovan with some water</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substances, to dihydropyridine derivatives, or to any of the 
excipients listed in section 6.1. 
• Severe hepatic impairment, biliary cirrhosis or cholestasis.
• Concomitant use of Amlovan with aliskiren-containing products in patients with diabetes 
mellitus or renal impairment (GFR <60 ml/min/1.73 m2
) (see sections 4.5 and 5.1). 
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6). 
• Severe hypotension. 
• Shock (including cardiogenic shock). 
• Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive 
cardiomyopathy and high grade aortic stenosis). 
• Haemodynamically unstable heart failure after acute myocardial infarction.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of amlodipine in hypertensive crisis have not been established.</p><p><u>Pregnancy </u></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Sodium- and/or volume-depleted patients </u></p><p>Excessive hypotension was seen in 0.4% of patients with uncomplicated hypertension treated with Amlovan in placebo-controlled studies. In patients with an activated renin-angiotensin system (such as volume- and/or salt-depleted patients receiving high doses of diuretics) who are receiving angiotensin receptor blockers, symptomatic hypotension may occur. Correction of this condition prior to administration of Amlovan or close medical supervision at the start of treatment is recommended.</p><p>If hypotension occurs with Amlovan, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.</p><p><u>Hyperkalaemia </u></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) should be undertaken with caution and with frequent monitoring of potassium levels.</p><p><u>Renal artery stenosis</u></p><p>Amlovan should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients.</p><p>&nbsp;</p><p><u>Kidney transplantation </u></p><p>To date there is no experience of the safe use of Amlovan in patients who have had a recent kidney transplantation.</p><p><u>Hepatic impairment </u></p><p>Valsartan is mostly eliminated unchanged via the bile. The half life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Particular caution should be exercised when administering Amlovan to patients with mild to moderate hepatic impairment or biliary obstructive disorders. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan.</p><p><u>Renal impairment</u></p><p>No dosage adjustment of Amlovan is required for patients with mild to moderate renal impairment (GFR &gt;30 ml/min/1.73 m2 ). Monitoring of potassium levels and creatinine is advised in moderate renal impairment.</p><p><u>Primary hyperaldosteronism</u></p><p>Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is affected by the primary disease.</p><p><u>Angioedema </u></p><p>Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx and/or tongue, has been reported in patients treated with&nbsp;valsartan. Some of these patients previously experienced angioedema with other medicinal products, including ACE inhibitors. Amlovan should be discontinued immediately in patients who develop angioedema and should not be re-administered.</p><p>&nbsp;</p><p><u>Heart failure/post-myocardial infarction </u></p><p>As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan. Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function.</p><p>In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.</p><p>Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p><u>Aortic and mitral valve stenosis</u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from mitral stenosis or significant aortic stenosis that is not high grade.</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy. Amlovan has not been studied in any patient population other than hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions common to the combination&nbsp;</u></p><p>No drug-drug interaction studies have been performed with Amlovan and other medicinal products.</p><p><em><u>To be taken into account with concomitant use </u></em></p><p><em>Other antihypertensive agents</em></p><p>Commonly used antihypertensive agents (e.g. alpha blockers, diuretics) and other medicinal products which may cause hypotensive adverse effects (e.g. tricyclic antidepressants, alpha blockers for treatment of benign prostate hyperplasia) may increase the antihypertensive effect of the combination.</p><p><u>Interactions linked to amlodipine</u></p><p><em><u>Concomitant use not recommended</u></em></p><p><em>Grapefruit or grapefruit juice</em></p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</p><p><em><u>Caution required with concomitant use</u></em></p><p><em>CYP3A4 inhibitors </em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>&nbsp;</p><p>CYP3A4 <em>inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum)</em></p><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum).</p><p><em>Simvastatin</em></p><p>Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine.</p><p><em>Dantrolene (infusion) </em></p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><em><u>To be taken into account with concomitant use</u></em></p><p><em>Others </em></p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.</p><p><u>Interactions linked to valsartan </u></p><p><u><em>Concomitant use not recommended</em></u></p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, including valsartan. Therefore, careful monitoring of serum lithium levels is recommended during concomitant use. If a diurectic is also used, the risk of lithium toxicity may presumably be increased further with Amlovan.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</em></p><p>If a medicinal product that affects potassium levels is to be prescribed in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p>&nbsp;</p><p><u><em>Caution required with concomitant use</em></u></p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs</em></p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p><em>Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)</em></p><p>The results of an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Coadministration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</p><p><em>Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren</em></p><p>Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><em>Others </em></p><p>In monotherapy with valsartan, no interactions of clinical significance have been found with the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>Amlodipine </em></p><p>The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section 5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p>&nbsp;</p><p><em>Valsartan</em></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>&nbsp;The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</p></td></tr></tbody></table><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3&ndash;7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. No information is available regarding the use of Amlovan during breast-feeding, therefore Amlovan is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><u>Fertility </u></p><p>There are no clinical studies on fertility with Amlovan.</p><p><em>Valsartan </em></p><p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>&nbsp;</p><p><em>Amlodipine </em></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients taking Amlovan and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.</p><p>Amlodipine can have mild or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of Amlovan has been evaluated in five controlled clinical studies with 5,175 patients, 2,613 of whom received valsartan in combination with amlodipine. The following adverse reactions were found to be the most frequently occurring or the most significant or severe: nasopharyngitis, influenza, hypersensitivity, headache, syncope, orthostatic hypotension, oedema, pitting oedema, facial oedema, oedema peripheral, fatigue, flushing, asthenia and hot flush.</p><p><u>Tabulated list of adverse reactions </u></p><p>Adverse reactions have been ranked under headings of frequency using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>MedDRA System organ class</strong></p></td><td rowspan="2"><p><strong>Adverse reactions</strong></p></td><td colspan="3"><p><strong>Frequency</strong></p></td></tr><tr><td><p><strong>Amlovan</strong></p></td><td><p><strong>Amlodipine</strong></p></td><td><p><strong>Valsartan</strong></p></td></tr><tr><td rowspan="2"><p>Infections and infestations</p></td><td><p>Nasopharyngitis</p></td><td><p>Common</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Influenza</p></td><td><p>Common</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td><p>Haemoglobin and haematocrit decreased</p></td><td><p>--</p></td><td><p>--</p></td><td><p>Not known</p></td></tr><tr><td><p>Leukopenia</p></td><td><p>--</p></td><td><p>Very rare</p></td><td><p>--</p></td></tr><tr><td><p>Neutropenia</p></td><td><p>--</p></td><td><p>--</p></td><td><p>Not known</p></td></tr><tr><td><p>Thrombocytopenia, sometimes with purpura</p></td><td><p>--</p></td><td><p>Very rare</p></td><td><p>Not known</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Hypersensitivity</p></td><td><p>Rare</p></td><td><p>Very rare</p></td><td><p>Not known</p></td></tr><tr><td rowspan="3"><p>Metabolism and nutrition disorders</p></td><td><p>Anorexia</p></td><td><p>Uncommon</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Hypercalcaemia</p></td><td><p>Uncommon</p></td><td><p>--</p></td><td><p>--</p></td></tr><tr><td><p>Hyperglycaemia</p></td><td><p>--</p></td><td><p>Very rare</p></td><td><p>--</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:755px"><tbody><tr><td rowspan="4" style="width:235px"><p>&nbsp;</p></td><td style="width:267px"><p>Hyperlipidaemia</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Hyperuricaemia</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Hypokalaemia</p></td><td style="width:85px"><p>Common</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Hyponatraemia</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td rowspan="5" style="width:235px"><p>Psychiatric disorders</p></td><td style="width:267px"><p>Depression</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Anxiety</p></td><td style="width:85px"><p>Rare</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Insomnia/sleep disorders</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Mood swings</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Confusion</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Rare</p></td><td style="width:81px"><p>--</p></td></tr><tr><td rowspan="12" style="width:235px"><p>Nervous system disorders</p></td><td style="width:267px"><p>Coordination abnormal</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Dizziness</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>Common</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Dizziness postural</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Dysgeusia</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Extrapyramidal syndrome</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Not known</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Headache</p></td><td style="width:85px"><p>Common</p></td><td style="width:82px"><p>Common</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Hypertonia</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Very rare</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Paraesthesia</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Peripheral neuropathy, neuropathy</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Very rare</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Somnolence</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>Common</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Syncope</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr><tr><td style="width:267px"><p>Tremor</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:81px"><p>--</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:757px"><tbody><tr><td style="width:235px"><p>&nbsp;</p></td><td style="width:262px"><p dir="rtl">Hypoesthesia</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td rowspan="2" style="width:235px"><p>Eye disorders</p></td><td style="width:262px"><p>Visual disturbance</p></td><td style="width:76px"><p>Rare</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Visual impairment</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td rowspan="2" style="width:235px"><p>Ear and labyrinth disorders</p></td><td style="width:262px"><p>Tinnitus</p></td><td style="width:76px"><p>Rare</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Vertigo</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td></tr><tr><td rowspan="5" style="width:235px"><p>Cardiac disorders</p></td><td style="width:262px"><p>Palpitations</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>Common</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Syncope</p></td><td style="width:76px"><p>Rare</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Tachycardia</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Very rare</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Myocardial infarction</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Very rare</p></td><td style="width:82px"><p>--</p></td></tr><tr><td rowspan="4" style="width:235px"><p>Vascular disorders</p></td><td style="width:262px"><p>Flushing</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Common</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Hypotension</p></td><td style="width:76px"><p>Rare</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Orthostatic hypotension</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Vasculitis</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Very rare</p></td><td style="width:82px"><p>Not known</p></td></tr><tr><td rowspan="4" style="width:235px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="width:262px"><p>Cough</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>Very rare</p></td><td style="width:82px"><p>Uncommon</p></td></tr><tr><td style="width:262px"><p>Dyspnoea</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Pharyngolaryngeal pain</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:262px"><p>Rhinitis</p></td><td style="width:76px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td></tr><tr><td style="width:235px"><p>Gastrointestinal disorders</p></td><td style="width:262px"><p>Abdominal discomfort, abdominal pain upper</p></td><td style="width:76px"><p>Uncommon</p></td><td style="width:85px"><p>Common</p></td><td style="width:82px"><p>Uncommon</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:759px"><tbody><tr><td rowspan="10" style="width:236px"><p>&nbsp;</p></td><td style="width:260px"><p>Change of bowel habit</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Constipation</p></td><td style="width:87px"><p>Uncommon</p></td><td style="width:88px"><p>--</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Diarrhoea</p></td><td style="width:87px"><p>Uncommon</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Dry mouth</p></td><td style="width:87px"><p>Uncommon</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Dyspepsia</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Gastritis</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Gingival hyperplasia</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Nausea</p></td><td style="width:87px"><p>Uncommon</p></td><td style="width:88px"><p>Common</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Pancreatitis</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Vomiting</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td rowspan="3" style="width:236px"><p>Hepatobiliary disorders</p></td><td style="width:260px"><p>Liver function test abnormal, including blood bilirubin increase</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare*</p></td><td style="width:85px"><p>Not known</p></td></tr><tr><td style="width:260px"><p>Hepatitis</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Intrahepatic cholestasis, jaundice</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>--</p></td></tr><tr><td rowspan="7" style="width:236px"><p>Skin and subcutaneous tissue disorders</p></td><td style="width:260px"><p>Alopecia</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Angioedema</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>Not known</p></td></tr><tr><td style="width:260px"><p>Dermatitis bullous</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>--</p></td><td style="width:85px"><p>Not known</p></td></tr><tr><td style="width:260px"><p>Erythema</p></td><td style="width:87px"><p>Uncommon</p></td><td style="width:88px"><p>--</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Erythema multiforme</p></td><td style="width:87px"><p>--</p></td><td style="width:88px"><p>Very rare</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Exanthema</p></td><td style="width:87px"><p>Rare</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr><tr><td style="width:260px"><p>Hyperhidrosis</p></td><td style="width:87px"><p>Rare</p></td><td style="width:88px"><p>Uncommon</p></td><td style="width:85px"><p>--</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:761px"><tbody><tr><td rowspan="9" style="width:239px"><p>&nbsp;</p></td><td style="width:263px"><p>Photosensitivity reaction</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Pruritus</p></td><td style="width:60px"><p>Rare</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>Not known</p></td></tr><tr><td style="width:263px"><p>Purpura</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Rash</p></td><td style="width:60px"><p>Uncommon</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>Not known</p></td></tr><tr><td style="width:263px"><p>Skin discolouration</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Urticaria and other forms of rash</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Very rare</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Exfoliative dermatitis</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Very rare</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Stevens-Johnson syndrome</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Very rare</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Quincke oedema</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Very rare</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:239px"><p>&nbsp;</p></td><td style="width:263px"><p>Toxic Epidermal Necrolysis</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Not Known</p></td><td style="width:87px"><p>--</p></td></tr><tr><td rowspan="7" style="width:239px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="width:263px"><p>Arthralgia</p><p>&nbsp;</p></td><td style="width:60px"><p>Uncommon</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Back pain</p></td><td style="width:60px"><p>Uncommon</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Joint swelling</p></td><td style="width:60px"><p>Uncommon</p></td><td style="width:82px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Muscle spasm</p></td><td style="width:60px"><p>Rare</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Myalgia</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>Not known</p></td></tr><tr><td style="width:263px"><p>Ankle swelling</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Common</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Sensation of heaviness</p></td><td style="width:60px"><p>Rare</p></td><td style="width:82px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td rowspan="4" style="width:239px"><p>Renal and urinary disorders</p></td><td style="width:263px"><p>Blood creatinine increased</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>--</p></td><td style="width:87px"><p>Not known</p></td></tr><tr><td style="width:263px"><p>Micturition disorder</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Nocturia</p></td><td style="width:60px"><p>--</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:263px"><p>Pollakiuria</p></td><td style="width:60px"><p>Rare</p></td><td style="width:82px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:763px"><tbody><tr><td rowspan="2" style="width:238px"><p>&nbsp;</p></td><td style="width:267px"><p>Polyuria</p></td><td style="width:83px"><p>Rare</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Renal failure and impairment</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>Not known</p></td></tr><tr><td rowspan="3" style="width:238px"><p>Reproductive system and breast disorders</p></td><td style="width:267px"><p>Impotence</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Erectile dysfunction</p></td><td style="width:83px"><p>Rare</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Gynaecomastia</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td rowspan="10" style="width:238px"><p>General disorders and administration site conditions</p></td><td style="width:267px"><p>Asthenia</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Discomfort, malaise</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Fatigue</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>Common</p></td><td style="width:87px"><p>Uncommon</p></td></tr><tr><td style="width:267px"><p>Facial oedema</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Flushing, hot flush</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Non cardiac chest pain</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Oedema</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>Common</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Oedema peripheral</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Pain</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Pitting oedema</p></td><td style="width:83px"><p>Common</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>--</p></td></tr><tr><td rowspan="3" style="width:238px"><p>Investigations</p></td><td style="width:267px"><p>Blood potassium increased</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>--</p></td><td style="width:87px"><p>Not known</p></td></tr><tr><td style="width:267px"><p>Weight increase</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr><tr><td style="width:267px"><p>Weight decrease</p></td><td style="width:83px"><p>--</p></td><td style="width:85px"><p>Uncommon</p></td><td style="width:87px"><p>--</p></td></tr></tbody></table><p>* Mostly consistent with cholestasis</p><p>&nbsp;</p><p><u>Additional information on the combination</u></p><p>Peripheral oedema, a recognised side effect of amlodipine, was generally observed at a lower incidence in patients who received the amlodipine/valsartan combination than in those who received amlodipine alone. In double-blind, controlled clinical trials, the incidence of peripheral oedema by dose was as follows :</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" rowspan="2"><p>% of patients who experienced peripheral oedema</p></td><td colspan="5"><p><strong>Valsartan (mg)</strong></p></td></tr><tr><td><p>0</p></td><td><p>40</p></td><td><p>80</p></td><td><p>160</p></td><td><p>320</p></td></tr><tr><td rowspan="4"><p><strong>Amlodipine (mg)</strong></p></td><td><p>0</p></td><td><p>3.0</p></td><td><p>5.5</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>0.9</p></td></tr><tr><td><p>2.5</p></td><td><p>8.0</p></td><td><p>2.3</p></td><td><p>5.4</p></td><td><p>2.4</p></td><td><p>3.9</p></td></tr><tr><td><p>5</p></td><td><p>3.1</p></td><td><p>4.8</p></td><td><p>2.3</p></td><td><p>2.1</p></td><td><p>2.4</p></td></tr><tr><td><p>10</p></td><td><p>10.3</p></td><td><p>NA</p></td><td><p>NA</p></td><td><p>9.0</p></td><td><p>9.5</p></td></tr></tbody></table><p>The mean incidence of peripheral oedema evenly weighted across all doses was 5.1% with the amlodipine/valsartan combination.</p><p><u>Additional information on the individual components</u></p><p>Adverse reactions previously reported with one of the individual components (amlodipine or valsartan) may be potential adverse reactions with Amlovan as well, even if not observed in clinical trials or during the post-marketing period.</p><p><u>Amlodipine </u></p><p><em>Common&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </em>Somnolence, dizziness, palpitations, abdominal pain, nausea, ankle swelling.</p><p><em>Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</em>Insomnia, mood changes (including anxiety), depression, tremor, dysgeusia, syncope, hypoesthesia, visual&nbsp;disturbance (including diplopia), tinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura,skin&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;discolouration,&nbsp;hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder,&nbsp;increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease.</p><p>&nbsp;</p><p><em>Rare&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</em>Confusion.</p><p>Very rare&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation),&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;vasculitis,pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema,&nbsp; erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; syndrome, Quincke oedema,&nbsp; &nbsp;photosensitivity.</p><p>* mostly consistent with cholestasis</p><p>Exceptional cases of extrapyramidal syndrome have been reported.</p><p>&nbsp;</p><p><u>Valsartan</u></p><p><em>Not known&nbsp; &nbsp; </em>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Decrease in haemoglobin, decrease in haematocrit, neutropenia, thrombocytopenia, increase of serum potassium, elevation of liver function values including increase of serum bilirubin, renal failure and impairment, elevation&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; of serum creatinine, angioedema, myalgia, vasculitis, hypersensitivity including serum sickness.</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" align="left"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p>&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" align="left"><tbody><tr><td><p><strong>For UAE </strong></p><p style="text-align:center">&nbsp;&bull; Pharmacovigilance &amp; Medical Device section</p><p>&nbsp;&bull; P.O.Box: 1853</p><p>  &bull; Tel: 80011111</p><p>&bull; Email: pv@moh.gov.ae</p><p>&nbsp;&bull; Drug Department Ministry of Health &amp; Prevention</p><p>&nbsp;Dubai</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" align="left"><tbody><tr><td><p><strong>For Oman</strong></p><p>&bull; Department of Pharmacovigilance &amp; Drug Information</p><p>&bull; Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>&bull; Ministry of Health, Sultanate of Oman</p><p>&bull; Phone Nos. 22357687 / 22357686</p><p>&bull; Fax: 22358489</p><p>&bull; Email: dg-padc@moh.gov.om</p><p>&bull; Website: www.moh.gov.om</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>There is no experience of overdose with Amlovan. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p><u>Treatment</u></p><p>If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption. Clinically significant hypotension due to Amlovan overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Both valsartan and amlodipine are unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II antagonists, combinations; angiotensin II antagonists and calcium channel blockers, ATC code: C09DB01</p><p>Amlovan combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p><u>Amlodipine/Valsartan</u></p><p>The combination of amlodipine and valsartan produces dose-related additive reduction in blood pressure across its therapeutic dose range. The antihypertensive effect of a single dose of the combination persisted for 24 hours.</p><p>&nbsp;</p><p><em>Placebo-controlled trials</em></p><p>Over 1,400 hypertensive patients received Amlovan once daily in two placebo-controlled trials. Adults with mild to moderate uncomplicated essential hypertension (mean sitting diastolic blood pressure &ge;95 and &lt;110 mmHg) were enrolled. Patients with high cardiovascular risks &ndash; heart failure, type I and poorly controlled type II diabetes and history of myocardial infarction or stroke within one year &ndash; were excluded.</p><p>&nbsp;</p><p><em>Active-controlled trials in patients who were non-responders to monotherapy </em></p><p>A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure &lt;90 mmHg at the end of the trial) in patients not adequately controlled on valsartan 160 mg in 75% of patients treated with amlodipine/valsartan 10 mg/160 mg and 62% of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53% of patients remaining on valsartan 160 mg. The addition of amlodipine 10 mg and 5 mg produced an additional reduction in systolic/diastolic blood pressure of 6.0/4.8 mmHg and 3.9/2.9 mmHg, respectively, compared to patients who remained on valsartan 160 mg only.</p><p>A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure &lt;90 mmHg at the end of the trial) in patients not adequately controlled on amlodipine 10 mg in 78% of patients treated with amlodipine/valsartan 10 mg/160 mg, compared to 67% of patients remaining on amlodipine 10 mg. The addition of valsartan 160 mg produced an additional reduction in systolic/diastolic blood pressure of 2.9/2.1 mmHg compared to patients who remained on amlodipine 10 mg only.</p><p>Amlovan was also studied in an active-controlled study of 130 hypertensive patients with mean sitting diastolic blood pressure &ge;110 mmHg and &lt;120 mmHg. In this study (baseline blood pressure 171/113 mmHg), an Amlovan regimen of 5 mg/160 mg titrated to 10 mg/160 mg reduced sitting blood pressure by 36/29 mmHg as compared to 32/28 mmHg with a regimen of lisinopril/hydrochlorothiazide 10 mg/12.5 mg titrated to 20 mg/12.5 mg.</p><p>In two long-term follow-up studies the effect of Amlovan was maintained for over one year. Abrupt withdrawal of Amlovan has not been associated with a rapid increase in blood pressure.</p><p>Age, gender, race or body mass index (&ge;30 kg/m2 , &lt;30 kg/m2 ) did not influence the response to Amlovan.</p><p>Amlovan has not been studied in any patient population other than hypertension. Valsartan has been studied in patients with post myocardial infarction and heart failure. Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.</p><p><u>Amlodipine</u></p><p>The amlodipine component of Amlovan inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure. Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.</p><p>Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.</p><p>Plasma concentrations correlate with effect in both young and elderly patients.</p><p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.</p><p>As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.</p><p>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or humans. In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.</p><p><em>Use in patients with hypertension</em></p><p>A randomised double-blind morbidity-mortality study called the Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5-10 mg/day (calcium channel blocker) or lisinopril 10-40 mg/day (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/day in mild to moderate hypertension. A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9 years. The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (&gt;6 months prior to enrollment) or&nbsp;documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol &lt;35 mg/dl or &lt;0.906 mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%). The primary endpoint was a composite of fatal coronary heart disease or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipinebased therapy and chlorthalidone-based therapy: risk ratio (RR) 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p>&nbsp;</p><p><u>Valsartan </u></p><p>Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT1, which is responsible for the known actions of angiotensin II. The increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may stimulate the unblocked receptor subtype AT2, which appears to counterbalance the effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000-fold) greater affinity for the AT1 receptor than for the AT2 receptor.</p><p>Valsartan does not inhibit ACE, also known as kininase II, which converts angiotensin I to angiotensin II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (p &lt;0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9%, respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced coughing, compared to 68.5% of those treated with an ACE inhibitor (p &lt;0.05). Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.</p><p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak drop in blood pressure is achieved within 4&ndash;6 hours. The antihypertensive effect persists over 24 hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained&nbsp;within 2&ndash;4 weeks and is sustained during long-term therapy. Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.</p><p>&nbsp;</p><p><u>Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an ARB.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and ARBs.</p><p>ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic nephropathy (see section 4.4).</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Linearity</u></p><p>Amlodipine and valsartan exhibit linear pharmacokinetics.</p><p><u>Amlodipine/Valsartan </u></p><p>Following oral administration of Amlovan, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6&ndash;8 hours, respectively. The rate and extent of absorption of Amlovan are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.</p><p><u>Amlodipine</u></p><p><em>Absorption</em>: After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6&ndash;12 hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.</p><p><em>Distribution</em>: Volume of distribution is approximately 21 l/kg. In vitro studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.</p><p><em>Biotransformation</em>: Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.</p><p><em>Elimination</em>: Amlodipine elimination from plasma is biphasic, with a terminal elimination halflife of approximately 30 to 50 hours. Steady-state plasma levels are reached after continuous administration for 7&ndash;8 days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.</p><p>&nbsp;</p><p><u>Valsartan</u></p><p><em>Absorption</em>: Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p><em>Distribution</em>: The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97%), mainly serum albumin.</p><p><em>Biotransformation</em>: Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><em>Elimination</em>: Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p><u><em>Special populations </em></u></p><p><u><em>Paediatric population (age below 18 years)</em></u></p><p>No pharmacokinetic data are available in the paediatric population.</p><p><em><u>Elderly (age 65 years or over) </u></em></p><p>Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.</p><p><em><u>Renal impairment </u></em></p><p>The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.</p><p><em><u>Hepatic impairment</u></em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic impairment have decreased clearance of amlodipine with resulting increase of approximately 40&ndash;60% in AUC. On average, in patients with mild to moderate chronic liver disease exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Caution should be exercised in patients with liver disease (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Amlodipine/Valsartan</em></p><p>Adverse reactions observed in animal studies with possible clinical relevance were as follows:</p><p>Histopathological signs of inflammation of the glandular stomach was seen in male rats at an exposure of about 1.9 (valsartan) and 2.6 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine. At higher exposures, there were ulceration and erosion of the stomach mucosa in both females and males. Similar changes were also seen in the valsartan alone group (exposure 8.5&ndash;11.0 times the clinical dose of 160 mg valsartan).</p><p>An increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an exposure of 8&ndash;13 (valsartan) and 7&ndash;8 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine. Similar changes were found in the valsartan alone group (exposure 8.5&ndash;11.0 times the clinical dose of 160 mg valsartan).</p><p>In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12 (valsartan) and 10 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg&nbsp;amlodipine. Dilated ureters were also found in the valsartan alone group (exposure 12 times the clinical dose of 160 mg valsartan). There were only modest signs of maternal toxicity (moderate reduction of body weight) in this study. The no-observed-effect-level for developmental effects was observed at 3- (valsartan) and 4- (amlodipine) fold the clinical exposure (based on AUC).</p><p>For the single compounds there was no evidence of mutagenicity, clastogenicity or carcinogenicity.</p><p>&nbsp;</p><p><em>Amlodipine </em></p><p><u>Reproductive toxicology </u></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><u>Impairment of fertility</u></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p><u>Carcinogenesis, mutagenesis</u></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>* Based on patient weight of 50 kg.</p><p>Valsartan</p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal&nbsp;opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised blood urea nitrogen, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In marmosets at comparable doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy including raised blood urea nitrogen and creatinine.</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Amlovan 5/160 mg film coated tablets Composition Formula</strong></p><p><strong>Name of Ingredients</strong></p></td><td><p><strong>Unit Dose (mg)</strong></p></td></tr><tr><td><p>Valsartan</p></td><td><p>160.000</p></td></tr><tr><td><p>Amlodipine Besylate</p></td><td><p>6.935</p></td></tr><tr><td><p>Avicel PH 102</p></td><td><p>254.065</p></td></tr><tr><td><p>Crospovidone NF</p></td><td><p>41.500</p></td></tr><tr><td><p>Colloidal Silicon Dioxide</p></td><td><p>3.000</p></td></tr><tr><td><p>Magnesium Stearate</p></td><td><p>4.500</p></td></tr><tr><td><p><strong>Core Tablet Weight</strong></p></td><td><p><strong>470.000</strong></p></td></tr><tr><td><p><strong>Coating</strong></p></td><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:461px"><tbody><tr><td style="width:355px"><p>Instacoat Universal A05G11327 Yellow</p></td><td style="width:105px"><p>12.000</p></td></tr><tr><td style="width:355px"><p>Purified Water BP</p></td><td style="width:105px"><p><strong>q.s</strong></p></td></tr><tr><td style="width:355px"><p><strong>Total</strong></p></td><td style="width:105px"><p><strong>486.000</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Amlovan 10/160 mg film coated tablets Composition Formula</strong></p><p><strong>Name of Ingredients</strong></p></td><td><p><strong>Unit Dose (mg)</strong></p></td></tr><tr><td><p>Valsartan</p></td><td><p>160.000</p></td></tr><tr><td><p>Amlodipine Besylate</p></td><td><p>13.870</p></td></tr><tr><td><p>Avicel PH 102</p></td><td><p>247.130</p></td></tr><tr><td><p>Crospovidone NF</p></td><td><p>41.500</p></td></tr><tr><td><p>Colloidal Silicon Dioxide</p></td><td><p>3.000</p></td></tr><tr><td><p>Magnesium Stearate</p></td><td><p>4.500</p></td></tr><tr><td><p><strong>Core Tablet Weight</strong></p></td><td><p><strong>470.000</strong></p></td></tr><tr><td><p><strong>Coating</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Instacoat Universal A05G11323 Yellow</p></td><td><p>12.000</p></td></tr><tr><td><p>Purified Water BP</p></td><td><p><strong>q.s</strong></p></td></tr><tr><td><p><strong>Total</strong></p></td><td><p><strong>486.000</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months / 2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not Store above 30&deg;C</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OPA/AL/PVC and Aluminum Foil</p><p>Pack sizes: Each Pack of Amlovan contains 28 tablets (7 tablets/blister)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>